APOE genotype-dependent modulation of astrocyte chemokine CCL3 production: Astrocytic Chemokine Modulation by APOE
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Apolipoprotein E (apoE) is well known as a regulator of cholesterol homeostasis, and is increasingly recognized to play a prominent role in the modulation of innate immune response, including cell-to-cell communication and migration. Alzheimer's disease (AD) is a slowly progressive neurodegenerative disorder characterized by neuroinflammation that appears to be an important component of the pathophysiology of the disease. Astrocytes are the majority cell type in brain, exerting significant influence over a range of central nervous system activities, including microglial-mediated neuroinflammatory responses. As the resident innate immune effector cells of the brain, microglia respond to soluble chemical signals released from tissue during injury and disease by mobilizing to lesion sites, clearing toxic molecules, and releasing chemical signals of their own. While microglial-mediated neuroinflammation in the AD brain remains an area of intense investigation, the mechanisms underlying reinforcement and regulation of these aberrant microglial responses by astrocytes are largely unstudied. Moreover, although inheritance of APOE ɛ4 represents the greatest genetic risk factor for sporadic AD, the mechanism by which apoE isoforms differentially influence AD pathophysiology is unknown. Here we show that APOE ɛ4 genotype specifically modulates astrocyte secretion of potent microglial chemotactic agents, including CCL3, thus providing evidence that APOE modulation of central nervous system (CNS) innate immune response is mediated through astrocytes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Harold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326 · cited 1×
“APOE E4 genotype is the greatest genetic risk factor for sporadic AD (Harold et al., 2009).”
Wu, D. C., Jackson-Lewis, V., Vila, M., Tieu, K., Teismann, P., Vadseth, C., Choi, D.-K., Ischiropoulos, H., & Przedborski, S. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-05-01763.2002 · Cited by 1,183 · cited 2×
“…lateral sclerosis (ALS), multiple sclerosis (MS), spinal cord injury, stroke, Parkinson’s disease (PD), and AD (Festoff et al., 2006; Howell et al., 2010; Malm et al., 2008; Neumann et al., 2006; Seabrook et al., 2006; Van Den Bosch et al., 2002; Wu et al., 2002; Yrjanheikki et al., 1998).”
BackgroundApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse Models
Cramer, P. E., Cirrito, J. R., Wesson, D. W., Lee, C. Y. D., Karlo, J. C., Zinn, A. E., Casali, B. T., Restivo, J. L., Goebel, W. D., James, M. J., et al. (2012) · Science · doi:10.1126/science.1217697 · Cited by 1,050 · cited 3×
“LXR and RXR activation has also been shown to suppress neuroinflammation, increase Ab clearance, and reverse behavioral deficits in mouse models of AD (Cramer et al., 2012; Cui et al., 2012; Mandrekar-Colucci et al., 2012).”
BackgroundResultTetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia
Yrjänheikki, J., Keinänen, R., Pellikka, M., Hökfelt, T., & Koistinaho, J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15769 · Cited by 1,006 · cited 1×
“…lateral sclerosis (ALS), multiple sclerosis (MS), spinal cord injury, stroke, Parkinson’s disease (PD), and AD (Festoff et al., 2006; Howell et al., 2010; Malm et al., 2008; Neumann et al., 2006; Seabrook et al., 2006; Van Den Bosch et al., 2002; Wu et al., 2002; Yrjanheikki et al., 1998).”
BackgroundAlzheimer’s Disease Risk Gene CD33 Inhibits Microglial Uptake of Amyloid Beta
Griciuc, A., Serrano-Pozo, A., Parrado, A. R., Lesinski, A. N., Asselin, C. N., Mullin, K., Hooli, B., Choi, S. H., Hyman, B. T., & Tanzi, R. E. (2013) · Neuron · doi:10.1016/j.neuron.2013.04.014 · Cited by 1,004
El Khoury, J., Toft, M., Hickman, S. E., Means, T. K., Terada, K., Geula, C., & Luster, A. D. (2007) · Nature Medicine · doi:10.1038/nm1555 · Cited by 915
ApoE Promotes the Proteolytic Degradation of Aβ
Jiang, Q., Lee, C. Y. D., Mandrekar, S., Wilkinson, B., Cramer, P., Zelcer, N., Mann, K., Lamb, B., Willson, T. M., Collins, J. L., et al. (2008) · Neuron · doi:10.1016/j.neuron.2008.04.010 · Cited by 876
Apolipoprotein E and Apolipoprotein E Receptors: Normal Biology and Roles in Alzheimer Disease
Holtzman, D. M., Herz, J., & Bu, G. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006312 · Cited by 782 · cited 1×
“Secreted apoE is known to bind cell-surface receptors (Holtzman et al., 2012), thereby initiating signal transduction cas- cades that subsequently alter a variety of cellular processes, including cell motility (Cudaback et al., 2011) and chemical secretion (Keene et al., 2011; LaDu et al., 2001).”
BackgroundSullivan, P. M., Mezdour, H., Aratani, Y., Knouff, C., Najib, J., Reddick, R. L., Quarfordt, S. H., & Maeda, N. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.29.17972 · Cited by 575 · cited 2×
“Maeda and colleagues (Sullivan et al., 1997; Xu et al., 1996) previously generated transgenic “humanized” mice homozygous for APOE E2, E3, or E4, providing a useful animal model for investigation of APOE influence of inflammatory response.”
BackgroundGarwood, C. J., Pooler, A. M., Atherton, J., Hanger, D. P., & Noble, W. (2011) · Cell Death & Disease · doi:10.1038/cddis.2011.50 · Cited by 379 · cited 1×
“Such activation results in robust elaboration of cytokines (Carrero et al., 2012; Garwood et al., 2011), which are diffusible cell-to-cell signaling molecules of the broader immune system.”
Background
Cited by
Tau and neuroinflammation: what impact for Alzheimer's disease and tauopathies?
Laurent, C., Buée, L., & Blum, D. (2018) · Biomedical Journal · doi:10.1016/j.bj.2018.01.003 · Cited by 348
“Of interest, APOE4 genotype, the strongest genetic risk factor for sporadic AD, was observed to favor astrocytic CCL3 production [151].”
BackgroundAstrogliosis: An integral player in the pathogenesis of Alzheimer's disease
Osborn, L. M., Kamphuis, W., Wadman, W. J., & Hol, E. M. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.01.001 · Cited by 312
Role of inflammatory molecules in the Alzheimer's disease progression and diagnosis
Bagyinszky, E., Giau, V. V., Shim, K., Suk, K., An, S. S. A., & Kim, S. (2017) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2017.03.031 · Cited by 262
Tai, L. M., Ghura, S., Koster, K. P., Liakaite, V., Maienschein‐Cline, M., Kanabar, P., Collins, N., Ben‐Aissa, M., Lei, A. Z., Bahroos, N., et al. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13072 · Cited by 165
The Chemokine MIP-1α/CCL3 impairs mouse hippocampal synaptic transmission, plasticity and memory
Marciniak, E., Faivre, E., Dutar, P., Alves Pires, C., Demeyer, D., Caillierez, R., Laloux, C., Buée, L., Blum, D., & Humez, S. (2015) · Scientific Reports · doi:10.1038/srep15862 · Cited by 148
Tzioras, M., Davies, C., Newman, A., Jackson, R., & Spires‐Jones, T. (2019) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12529 · Cited by 147
Microglial Malfunction: The Third Rail in the Development of Alzheimer's Disease
Mhatre, S. D., Tsai, C. A., Rubin, A. J., James, M. L., & Andreasson, K. I. (2015) · Trends in Neurosciences · doi:10.1016/j.tins.2015.08.006 · Cited by 134
Plaque-associated local toxicity increases over the clinical course of Alzheimer disease
Serrano-Pozo, A., Betensky, R. A., Frosch, M. P., & Hyman, B. T. (2016) · The American Journal of Pathology · doi:10.1016/j.ajpath.2015.10.010 · Cited by 100
Role of Chemokines in the Development and Progression of Alzheimer’s Disease
Wojcieszak, J., Kuczyńska, K., & Zawilska, J. B. (2022) · Journal of Molecular Neuroscience · doi:10.1007/s12031-022-02047-1 · Cited by 97
A multi‐hit hypothesis for an APOE4 ‐dependent pathophysiological state
Steele, O. G., Stuart, A. C., Minkley, L., Shaw, K., Bonnar, O., Anderle, S., Penn, A. C., Rusted, J., Serpell, L., Hall, C., et al. (2022) · European Journal of Neuroscience · doi:10.1111/ejn.15685 · Cited by 44
“…exhibit impaired migration, phagocytosis and clearance of cellular debris including Aβ, increased amoeboid structure and enhanced risk of cell death and promote neurotoxicity (Cash et al., 2012; Cudaback et al., 2015; Grainger et al., 2004; Lin et al., 2018; Muth et al., 2019; Vitek et al., 2009).”
BackgroundMutation-specific neuropathologic signatures in MAPT-associated frontotemporal lobar degeneration
Bogdani, M., Jadhav, V. S., Kraemer, B. C., Grabowski, T. J., Jayadev, S., Domoto-Reilly, K., Liachko, N. F., Bird, T. D., Dirk Keene, C., & Latimer, C. S. (2026) · Acta Neuropathologica · doi:10.1007/s00401-026-03047-w · Cited by 1
Metadata
- Authors
- Cudaback, E., Yang, Y., Montine, T. J., & Keene, C. D.
- Venue
- Glia
- Publisher
- Wiley
- Published
- 2014-08-04
- Volume
- 63
- Issue
- 1
- Pages
- 51-65
- ISSN
- 0894-1491 (ISSN-L)
- OpenAlex
- W1597989812
- Cited by
- 47
- References
- 28
- FWCI
- 2.53
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.